Merrimack Pharmaceuticals, Inc. (MACK) Scheduled to Post Earnings on Tuesday
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) will be issuing its quarterly earnings data before the market opens on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.
Merrimack Pharmaceuticals (NASDAQ:MACK) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.18) earnings per share for the quarter, missing the consensus estimate of ($1.37) by ($0.81). During the same period in the previous year, the business posted ($4.00) EPS. On average, analysts expect Merrimack Pharmaceuticals to post $-7 EPS for the current fiscal year and $-6 EPS for the next fiscal year.
Merrimack Pharmaceuticals, Inc. (MACK) opened at $11.71 on Friday. Merrimack Pharmaceuticals, Inc. has a 1 year low of $11.14 and a 1 year high of $67.90. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.45 and a current ratio of 2.45.
In related news, Director Ulrik B. Nielsen sold 7,896 shares of the company’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $14.23, for a total transaction of $112,360.08. Following the completion of the sale, the director now owns 22,781 shares of the company’s stock, valued at approximately $324,173.63. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ulrik B. Nielsen sold 14,756 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $14.46, for a total transaction of $213,371.76. Following the sale, the director now directly owns 37,437 shares of the company’s stock, valued at approximately $541,339.02. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,308 shares of company stock valued at $637,558. 8.53% of the stock is owned by corporate insiders.
A hedge fund recently raised its stake in Merrimack Pharmaceuticals stock. The Manufacturers Life Insurance Company grew its position in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) by 14.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 113,235 shares of the biopharmaceutical company’s stock after buying an additional 14,591 shares during the period. The Manufacturers Life Insurance Company owned 0.09% of Merrimack Pharmaceuticals worth $141,000 as of its most recent SEC filing.
MACK has been the subject of several research analyst reports. ValuEngine upgraded shares of Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. Zacks Investment Research downgraded shares of Merrimack Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Robert W. Baird reaffirmed a “hold” rating and set a $15.00 price objective on shares of Merrimack Pharmaceuticals in a research note on Friday, October 13th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $64.53.
Merrimack Pharmaceuticals Company Profile
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
Receive News & Stock Ratings for Merrimack Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.